Immunic, Inc. (IMUX)
NASDAQ
Key stats Fiscal year 2025
Income statement
- Net income
- -97,172,000
- Operating income
- -103,228,000
- Earnings per share
- -0.62
Balance sheet
- Total assets
- 24,052,000
- Total liabilities
- 30,725,000
- Shareholders' equity
- -6,673,000
- Cash and equivalents
- 15,483,000
- Current ratio
- 0.75
Cash flow and ratios
- Operating cash flow
- -85,806,000
- Free cash flow
- -85,967,000
Fiscal year end: · Source: SEC EDGAR
Immunic, Inc. trades on NASDAQ under the ticker symbol IMUX. This page brings together its price chart, company profile, key financial figures and technical indicators.